SUMMARY Liver biopsies were performed on 51 regularly transfused patients with # thalassaemia, age range 5-36 (mean 18-6) years, who had received regular subcutaneous desferrioxamine (DFX) treatment for periods between one and eight years (40 for eight years). The biopsy specimens were examined by light microscopy and immunofluorescence for hepatitis B virus surface and core antigens (HBsAg and HBcAg), and the iron content was determined chemically. The results were compared with serum ferritin concentration and aspartate transaminase (AST) activity and with hepatitis B virus serology. Biopsy specimens, in which chemical liver iron had been determined in 12, were also available from 17 patients. Mean serum ferritin (± SD) had fallen from 5885 (3245) 
SUMMARY Liver biopsies were performed on 51 regularly transfused patients with # thalassaemia, age range 5-36 (mean 18-6) years, who had received regular subcutaneous desferrioxamine (DFX) treatment for periods between one and eight years (40 for eight years). The biopsy specimens were examined by light microscopy and immunofluorescence for hepatitis B virus surface and core antigens (HBsAg and HBcAg), and the iron content was determined chemically. The results were compared with serum ferritin concentration and aspartate transaminase (AST) activity and with hepatitis B virus serology. Biopsy specimens, in which chemical liver iron had been determined in 12, were also available from 17 patients. Mean serum ferritin (± SD) had fallen from 5885 (3245) jg/l to 1638 (976) pg/l in 36 patients after eight years' chelation, while mean (± SD) liver iron concentration had fallen from 2945 (900) yg/100 mg dry weight to 857 (435) jg/100 mg dry weight in 12 of them. All biopsy specimens examined were negative for HBs and HBc antigens. The presence of histological features of hepatitis was associated with increased liver iron content, increased fibrosis, and with progression of fibrosis between the two biopsies. Procollagen III peptide was assayed in 28 patients but did not correlate with the degree of hepatitis, fibrosis, or with chemical liver iron content. We conclude that with regular subcutaneous DFX, mean concentrations of serum ferritin and liver iron are maintained in these patients at about five and 10 times the normal value, respectively, and that progression of liver damage is more likely to be due to viral hepatitis, presumably related to the parenterally transmitted non-A, non-B agents than to iron overload.
Liver damage in regularly transfused patients with f thalassaemia major results from increased hepatic iron content and chronic hepatitis associated with transfusion.`1 Regular chelation with subcutaneous desferrioxamine (DFX) has been shown to produce negative iron balance in these patients with or without hepatitis.6'-1 On the other hand, hepatitis after transfusion remains a common complication which contributes to progressive liver damage. In this study we performed liver biopsies on 51 such patients receiving regular blood transfusions who had also received subcutaneous DFX for periods from one to eight years to determine the extent of liver damage and assess the value of serum ferritin concentrations and aspartate transaminase (AST) activity as indiAccepted for publication 27 May 1987 cators of liver iron content and liver damage, respectively. We also investigated a possible association between serum concentrations of procollagen type III peptide synthesis and liver disease.
Patients and methods
Liver biopsies were performed on 51 patients (22 females, 29 males, aged 8-36 (mean 18 6) years with f thalassaemia major, who had received blood transfusions every four to five weeks for four to 34 (mean 16-5) years to maintain a pre-transfusion haemoglobin above 10-5-l1 g/dl. Forty patients had received subcutaneous chelation for eight years, four for six years, and seven for one to five years. The biopsy was performed to determine the extent of liver damage and liver iron overload. Informed consent 1353 was obtained from each patient. Thirty four patients (66 7%) had received transfusions only in the United Kingdom. Most also received subcutaneous chelation with DFX 40-60 mg/kg on five to six nights each week. A few poorly compliant patients used infusions less often (two to four times weekly). The biopsies were performed using standard Menghini needles, except in two patients who had wedge biopsy of the liver when their spleens were removed. There were no complications related to the biopsies.
Each biopsy sample was divided into three parts for determination of chemical liver iron content, detection of hepatitis B antigens, and for histology. The specimens were analysed for chemical liver iron using the method described by Barry and Sherlock'2 (normal range 35-136 pg/100 mg dry weight). The presence of HbsAg and HBcAg in the biopsy specimens was investigated using immunofluorescence. Briefly, fresh liver tissue was snap frozen in OCT embedding compound and kept in liquid nitrogen until analysed. Sections (4 tm) were cut on to glass slides, dried under a fan for one hour, and fixed in cold acetone. The sections were washed in phosphate buffer saline (PBS) and then for 20 minutes with the appropriate dilutions of murine monoclonal antibodies to either HBsAg or HBcAg (raised in our laboratories). Normal mouse serum was used as negative control. The sections were incubated at room temperature for 30 minutes and then washed in PBS for 20 minutes. Fluorescent rabbit antiserum to mouse immunoglobulin (Dako Ltd, High Wycombe) was then added to each section and incubated at room temperature for 30 minutes and mounted under a coverslip in 50% glycerol in PBS. They were then viewed under ultraviolet light illumination on a Leitz Dialux 20 microscope.
HISTOLOGICAL ASSESSMENT
The specimens were assessed on several occasions by one histopathologist and finally reviewed by another. Samples obtained for histological assessment were adequate in most cases. There was homogeneous distribution of iron and inflammatory cells in both the percutaneous and wedge biopsy specimens., Fibrosis was also assessed. Degree of siderosis in hepatocytes, Kupffer cells, and endothelial cells was graded from 0-4, as shown by Perls's stain; grade I representing minimal amounts, and grade 4 the degree seen in hepatocytes in fully developed untreated haemochromatosis. Features of hepatitis were also classified into five grades: grade 0, no evidence of hepatitis; grade 1, scanty lymphocytic infiltrate; grade 2, obvious inflammatory cell infiltrate in the portal tracts and lobules with little or no liver damage; grade 3, lobular component and evidence of liver cell damage (acidophil bodies or piecemeal necrosis); grade 4, severe inflammatory infiltrate and liver cell damage. This method of grading was chosen rather than the more conventional classification of chronic persistent and chronic active hepatitis, because in our experience progression of liver disease in thalassaemic patients seemed to be mainly by portal fibrosis and focal lobular inflammation and necrosis rather than by piecemeal necrosis, the defining feature of chronic active hepatitis. Fibrosis was graded as follows: 0, no fibrosis; 1, portal expansion; 2, septum formation; 3, linking of portal tracts or perilobular fibrosis; 4, cirrhosis.
Serum ferritin was measured by immunoradiometric assay'3 before and during subcutaneous chelation. The normal ranges for our laboratories are 39-340 ig/l in males and 14-148 ig/l in females. Serum AST was measured throughout the study at intervals of three months or less. Normal values are less than 40 IU/l. Serological tests were carried out to determine the hepatitis B virus state of each patient. The immunoradiometric assay of Goodall et al'4 for HBsAg was used. Total antibodies to HBsAg, ABcAg, and HBeAg were measured using commercially available kits (Abbot Laboratories, Diagnostic Division).
Procollagen type III peptide is a biosynthetic precursor of collagen type III and was measured in serum as a possible indicator of the degree of hepatic fibrosis in these patients. The method used was a radioimmunoassay using an RIA-ghost kit (Behringwerke AG, Marburg, West Germany).
Current AST and serum ferritin results were compared with those before starting subcutaneous chelation. Liver biopsy specimens had been performed on 17 patients before chelation began, with chemical liver iron content measured in 12. Statistical (fig 3) . On the other hand, there was a significant overall correlation between degree of hepatic fibrosis and the severity of hepatitis (X2 = 22-8, p = 0-0001) (fig 4) .
AST was raised in 29 (37%) of the 51 patients. The mean serum ferritin concentration in 38 patients had dropped from 5885 (3245) ug/l to 1638 (976) pg/l (p < 0'0001) after eight years' subcutaneous DFX chelation. Mean chemical liver iron content in 12 patients had dropped from 2945(900) to 857 (435)pg/100 mg dry weight (p < 0.01) after five to eight years on the same treatment ( fig 5) . Abnormal serum AST was defined as an AST activity above the normal range for a period of six months at the start of subcutaneous DFX or at the time of this study. The AST activity remained normal in 10 (28%) and had improved in 18 (50%) of 36 tested. It deteriorated in four (11 %) and remained abnormal in a further four (11%), all eight of whom had shown severe siderosis and hepatitis (table 5) .
Previous biopsy specimens performed six to eight years ago were available from 17 patients. In 11 pa- tients there was no progression of fibrosis-grade I (n = 1), grade 2 (n = 4), grade 3 (n = 5), and grade 4 (n = 1); one showed an improvement (from grade 3 to 2) while five showed progression of fibrosis (table  6 ). In one of these five (aged 16 years) the progression was from grade 1 to 2; three (aged 17, 27, and 36 years) progressed to grade 3 from grades 2, 2, and 1, respectively, and one aged 18 years from grade 3 to 4 (cirrhosis). All these latter four patients showed M  12  1978  1190  2811  173  3  3  18  1985  1040  833   59   3  4  F  9  1978  11600  57  1  1  16  1985  2000  2166   1  2  F   10   1978  4800  70  1  2  17  1985  5000  3428  75  3  3  M  27  1977  10600  73  1  1  35  1985  2340  1600  26  3  3  M  21  1979  15000  2450  157  3  2  27  1985  1650  1250  31  3  3 1357 Post-transfusion hepatitis (due to HB or non-A, non-B viruses, or a combination) remains a major problem in these patients. Severe hepatitis assessed histologically strongly correlated with increased fibrosis in the whole group, and four of five patients showed histological features of severe hepatitis where fibrosis increased while receiving subcutaneous desferrioxamine for six to eight years. A similar observation was reported by Masera et al. 2 Patients with severe hepatitis also had significantly increased chemical liver iron content compared with those with moderate or no hepatitis, and this was more than could be anticipated from their serum ferritin values. De Virgilis et al' also observed increased hepatic iron content in patients with thalassaemia major and chronic active hepatitis and siderosis compared with those with siderosis alone, and found no correlation of liver iron with number of units transfused. The explanation of this higher liver iron content in the face of hepatitis is unclear, but the finding suggests that severe hepatitis may contribute to liver damage by both the chronic inflammatory process and by a higher liver iron content. Our finding that liver iron in patients with severe fibrosis (grades 3 and 4) was significantly higher than in those with minimal fibrosis (grades 0 and 1) may have resulted from the fact that most of the patients with severe fibrosis had severe hepatitis (fig 3) . The overall correlation of 85 1986 (table 3) , although seven of eight patients whose AST activity remained abnormal on eight years' follow up had both severe hepatitis and gross iron overload. Normal AST activities, however, did not exclude the presence of severe hepatitis.
About 50% of patients with moderate or severe hepatitis had antibodies in serum to hepatitis B virus components, although none had HBs or HBc antigens in the liver. These data indicate previous HBV infection, most probably acquired by blood transfusion.-It seems likely that continuing hepatitis is related more to non-A, non-B virus infection that also stems from blood transfusions.
Only five of 51 patients were found to have fully developed cirrhosis while 16 had severe fibrosis. The mean age of these 21 patients was 206 years. The incidence of severe fibrosis was therefore less, and in an older age group than previously reported by Jean et al. 3 These authors studied 86 liver biopsy specimens from patients in northern Italy in the years 1976-1981 who were receiving intramuscular desferrioxamine and subsequently subcutaneous desferrioxamine. In our study deterioration of liver fibrosis seemed to be more related to hepatitis incurred as a result of transfusion than to iron overload.
The fact that patients with minimal fibrosis were significantly younger than those with moderate or severe fibrosis may have been due to the differences in the time excess iron had been present but also to the effect of earlier chelation in the younger group. Interestingly, both patients with normal liver iron concentrations started subcutaneous desferrioxamine shortly after blood transfusions began.
In conclusion, early and continuous chelation is clearly effective in decreasing liver iron overload and delaying the onset of iron induced liver damage in patients with thalassaemia. Parenterally transmitted hepatitis, however, seems to be an important factor in the progression of liver cell damage and fibrosis. The reason for the association of increased hepatic iron with hepatitis found in this study is still unexplained. The serum ferritin concentration gave an overall indication of liver iron content, but in patients with severe hepatitis changes the serum ferritin was disproportionally low. Serum AST activity correlated better in this well chelated group with severity of hepatitis rather than with liver iron content.
